Psoriasis, a chronic inflammatory disease of the skin resulting from an uncontrolled immune response, affects more than 125 million people worldwide. OTEZLA offers a valuable treatment option for a spectrum of plaque psoriasis patients – patients who are treatment-na ve as well as patients who are treatment-experienced, including those previously treated with biologic agents or conventional systemic agents, said Scott Smith, President Inflammation & Immunology for Celgene Corporation. Clinical improvement as measured by sPGA scores of clear to almost clear were also demonstrated in both studies. Some systemics can also be used to treat psoriatic arthritis. It is often prescribed for moderate to severe plaque psoriasis, erythrodermic psoriasis (a medical emergency, where psoriasis completely covers the entirety of the skin), and some cases of pustular psoriasis. Methotrexate is usually taken once a week, in tablet form, or it can be given as an injection. Other potential side effects include nausea and sickness, diarrhoea, mouth ulcers, hair loss and skin rashes, however many people find that these can be controlled by altering the dose. Otezla (apremilast). Psoriasis is a chronic skin disorder that causes areas of thickened, inflamed, red skin, often covered with silvery scales. Some of the most common areas for plaques are the scalp, elbows, knees, and back (picture 1). Pustular psoriasis can also cause pus-filled blisters on the palms of the hands and soles of the feet. This drug is often used to treat moderate to severe psoriasis and/or psoriatic arthritis.
Apremilast is a drug for the treatment of certain types of psoriasis and psoriatic arthritis. It may also be useful for other immune system related inflammatory diseases. 6 In September 2014, the US FDA approved apremilast for the treatment of moderate to severe plaque psoriasis. Apremilast (Otezla) is not recommended for treating moderate to severe chronic plaque psoriasis in adults whose psoriasis has not improved with other treatments, or they have had side effects with these treatments in the past or there is a reason why they cannot have them. Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. These disfiguring skin lesions are often associated with numerous comorbidities, ranging from cardiovascular disease, autoimmune disease, and cancer to psychiatric/psychological disorders. Moderate-to-severe disease typically necessitates the use of systemic agents, whether it be traditional agents or biologics (e. 12 Subsequently, Celgene received FDA approval in September 2014 to further market the drug for the treatment of moderate-to-severe plaque psoriasis in patients for whom phototherapy or systemic therapy is appropriate. The safety profile of apremilast was also similar to that seen in the placebo- controlled phase of the study.
Psoriatic arthritis is a type of arthritis that causes pain and swelling of the joints and patches of scaly skin on some areas of the body. apremilast is also used to treat moderate to severe plaque psoriasis, which is a skin disease with red patches and white scales that don’t go away. Plaque psoriasis leads to skin patches that start off in small areas, about 1/8 of an inch wide. This is a rare and severe form of psoriasis, in which the skin surface becomes scaly and red. The condition may also be triggered by certain psoriasis treatments, and other medications such as corticosteroids or synthetic antimalarial drugs. Less potent drugs are used for mild-to-moderate psoriasis. Psoriasis continues to be one of the more difficult skin conditions to treat. Different medications may need to be used together or in rotation for best effect or to minimise side effects. Topical steroids are very useful for treating flexural psoriasis, some limited plaque psoriasis, scalp psoriasis (see scalp care below) and sebopsoriasis. Calcipotriol (also called calcipotriene) is effective and safe for mild to moderate chronic plaque psoriasis, scalp psoriasis and flexural psoriasis.
While the exact way in which Otezla helps improve symptoms of plaque psoriasis isn’t completely understood, Otezla works inside your body’s cells to reduce PDE4 activity, which is thought to help reduce inflammation. For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). Psoriasis is a systemic inflammatory condition characterised by raised scaly lesions on the skin. 5 Plaque psoriasis, also called psoriasis vulgaris, is the most common form of the disease, representing approximately 80 percent of cases. At week 16, some placebo-treated patients were randomized to one of the two apremilast groups, while others remained on placebo through week 24. Apremilast is used to treat active psoriatic arthritis. Psoriatic arthritis is a type of arthritis that causes pain and swelling of the joints and patches of scaly skin on some areas of the body. This medicine is also used to treat moderate to severe plaque psoriasis, which is a skin disease with red patches and white scales that don’t go away. Recent human clinical data on PDE4 inhibitors on skin diseases and in particular on psoriasis are available for apremilast. A small (19 patients) single arm, open-label pilot study was performed in subjects with moderate to severe plaque psoriasis. Drugs such as apremilast may also be used as maintenance therapy once remission has been induced by another drug and it may help prevent relapses often seen after withdrawal of, for example, CsA. 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. Aetna considers biological therapies adalimumab (Humira), apremilast (Otezla), etanercept (Enbrel), infliximab (Remicade), secukinumab (Cosentyx), and ustekinumab (Stelara) medically necessary for adults aged 18 years and older with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy when the following selection criteria are met:. Long-term disease control frequently requires some form of continuous therapy and consequent, predictable risks of toxicity. The assessment found that the general efficacy of adalimumab, alefacept, etanercept, infliximab, and ustekinumab for the treatment of moderate to severe plaque psoriasis was supported by multiple good to fair randomized controlled trials. Patients were also required to have active skin disease with one plaque psoriasis skin lesion 2 cm in size. The use of DMARDs other than methotrexate, leflunomide or sulfasalazine was not permitted 4 weeks of randomisation. 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Apremilast Advanced Patient Information
Small-molecule drugs that block errant cell signalling pathways are also being developed and could form the basis of much-needed new topical treatments. For moderate and severe cases, topical treatment is impractical, and the benefits of systemic therapies are generally considered to outweigh the risks. Pruritus – One of the main symptoms of plaque psoriasis. Skin biopsy can confirm the diagnosis of plaque psoriasis. Topical agents used (often concurrently) to treat plaque psoriasis include the following:. Systemic therapy should also be considered for patients with very active psoriatic arthritis, as well as for patients whose disease is physically, psychologically, socially, or economically disabling. Alteration of the balance of T-cell types. Consumer information about the arthritis drug apremilast (Otezla). Psoriatic arthritis is a disease that causes skin and joint inflammation. Psoriasis is a variable autoimmune skin disorder that cannot be cured but it can be controlled with topical and oral medications, phototherapy and biologics. In some patients it may be no more than a minor cosmetic problem, while in others it can cause quite serious problems with many remissions and flares. Plaque psoriasis, also called psoriasis vulgaris, is the most common type of psoriasis, accounting for about 80 of all cases. Phototherapy is frequently used in the treatment of moderate to severe psoriasis.